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Abstract: Human ageing is a complex and integrated gradual deterioration of cellular 
processes. There are nine major hallmarks of ageing, that include changes in DNA repair 
and DNA damage response, telomere shortening, changes in control over the expression 
and regulation of genes brought about by epigenetic and mRNA processing changes,  
loss of protein homeostasis, altered nutrient signaling, mitochondrial dysfunction, stem cell 
exhaustion, premature cellular senescence and altered intracellular communication.  
Like practically all other cellular processes, genes associated in features of ageing are 
regulated by miRNAs. In this review, I will outline each of the features of ageing, together 
with examples of specific miRNAs that have been demonstrated to be involved in each one. 
This will demonstrate the interconnected nature of the regulation of transcripts involved  
in human ageing, and the role of miRNAs in this process. Definition of the factors involved 
in degeneration of organismal, tissue and cellular homeostasis may provide biomarkers for 
healthy ageing and increase understanding of the processes that underpin the ageing 
process itself. 
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1. Introduction 
MicroRNAs (miRNAs) are short, non-coding RNA species that have a pivotal role in  
post-transcriptional regulation of gene expression. MicroRNAs associate with the RNA-induced 
silencing complex (RISC) and bind to the 3' untranslated region (UTR) of their target transcripts, 
resulting in reduction of gene expression by mRNA degradation or translational blocking [1].  
The specificity of miRNA:mRNA binding is brought about by complementarity of the “seed” sequence 
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of the miRNA (a tract of 7-8 nucleotides at the 5' end of the miRNA molecule) with a complementary 
sequence within the target mRNA [2]. The relatively short region of complementarity between miRNA 
and target results in many transcripts containing potential binding sites for a given miRNA, and a 
single miRNA therefore has the potential to regulate hundreds of different mRNA targets [3]. 
MicroRNAs are estimated to regulate as many as 60% of all human mRNAs, which represent 
practically all cellular and molecular functions [4]. MiRNAs are known to be key players in the 
regulation of transcripts involved in processes as diverse as embryonic development, differentiation, 
cellular proliferation, apoptosis, metabolism and adaptation to environmental stress [5]. Given the 
involvement of miRNA regulation in multiple cellular processes, it is unsurprising that this process 
plays a part in complex, multifactorial and environmentally-influenced cellular processes such as 
human disease and cellular and organismal ageing. 
The expression profile of miRNAs may be tissue specific and labile, although some miRNAs are 
common to most tissues. The precise pool of miRNAs that show age-related changes is influenced by 
the miRNA expression profile of the particular cell type or species studied, and may also reflect the 
features of ageing cells which differ between tissue types or species. The heterogeneous nature of 
tissues, together with the known cell- and sometimes species-specificity of miRNAs may make 
identification of all the major players associated with ageing in humans and other species in a single 
tissue a difficult proposition, and also raises issues with integration of datasets. However, ageing is 
characterized by a well-defined set of characteristics that are shared by most tissue types and are 
known as “hallmarks” of ageing [6]. MicroRNAs associated with specific “hallmarks” of ageing in 
humans and other species may identify miRNAs that have more general importance in the ageing 
process distinct from those which may have a more tissue-specific role. 
2. The Hallmarks of Ageing 
Ageing is characterized by a progressive deterioration of cellular processes in all tissues.  
Age-related changes are myriad, and involve almost every cellular and biological function pathway. 
There are several “hallmarks” of ageing, as recently described by Lopez-Otin et al. [6], see Figure 1. 
These include changes to genomic stability, brought about by accumulating DNA damage in the face 
of decreased DNA repair [7], the progressive shortening of telomeres as chromosomes age [8], 
changes in fine control of gene expression through epigenetic changes and deregulation of alternative 
splicing [9,10], changes to proteostatic processes such as ubiquitination, protein folding and trafficking [11], 
deregulation of nutrient sensing pathways such as mTOR and IGF1 signaling [12,13], mitochondrial 
dysfunction [14], cellular senescence [15], stem cell exhaustion [16] and alterations in intercellular 
communication such as heightened inflammatory response and disruption to cytokine expression [17]. 
Given the complexity of the changes that occur during the ageing process in man and other species, 
and the known role of miRNAs in mediating complex and interlinked pathways, it is unsurprising that 
miRNAs play a part in ageing, as in many other pivotal cellular processes. In this review, I will define 
some of the known pathways of ageing in man and other species, and outline the role of miRNA 
regulation of genes involved in each. 
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Figure 1. The hallmarks of eukaryotic ageing and the miRNAs that may interact with these 
pathways. MicroRNAs that have been to be associated with each feature are indicated. 
Those miRNAs that are known to be involved in more than one feature are given in bold, 
underlined text.
 
2.1. miRNAs and DNA Damage Response 
The association between miRNAs and DNA damage response falls into two categories; miRNAs 
that are regulated by DNA damage responses, and those which target components of the DNA damage 
response and DNA repair pathways themselves. 
2.1.1. miRNAs Regulated by the DNA Damage Response 
MiRNA biogenesis is a labile process, and miRNA expression is sensitive to many external stimuli. 
When damaged DNA is detected by the cell, double or single stranded DNA breaks produced through 
irradiation or as a result of base/nucleotide excision repair are detected by the Ataxia Telangiectasia 
Mutated (ATM) and Ataxia Telangiectasia Related (ATR) kinases. ATM and ATR activate the CHK1 
and CHK2 proteins, which in turn bring about cessation of growth and cellular apoptosis through a 
cascade involving the p53 and RB1 proteins [18]. The p53 protein plays a pivotal part in determining 
global miRNA levels through its role in modulating the maturation of primary miRNA transcripts [19]. 
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Studies in p53 deficient mouse embryonic fibroblast cells have indicated that one family of miRNAs, 
miR34a—miR34c has particular importance and are direct targets of p53 [20]. The action of p53 is 
also essential for induction of the related miRNAs miR-192, miR-194 and miR-215, which are  
up-regulated by genotoxic stress and are capable of inducing cell cycle arrest by causing increased 
expression of multiple transcripts involved in S phase and G1 and G2 checkpoints in human colon 
cancer samples [21] and human osteosarcoma cells [22]. 
2.1.2. miRNAs that Regulate Components of the DNA Damage Response and DNA Repair 
The DNA damage response is a complex, coordinated pathway of inter-regulated gene expression. 
Genes involved in multiple parts of this pathway are targeted by miRNAs. Firstly, the DNA damage 
transducer genes, ATM is itself targeted by miR-421 in Hela cells [23], whilst H2AX is regulated by 
miR-24 in terminally differentiated human blood cells [24]. Ectopic expression of miR-421 causes  
a phenotype resembling that seen in ATM patients characterized by cellular checkpoint changes  
and radiosensitivity [23], whereas miR-24 mediated suppression of H2AX causes sensitivity to  
gamma-radiation and genotoxic drugs [24]. Other components of the DNA damage response are also 
targeted by miRNAs; the TP53 gene itself which encodes p53 is targeted by miR-504 and miR-125b  
in several cell lines [25,26] whereas the CDKN1A/p21 gene was demonstrated to be directly regulated 
by miR-106b in samples from five different solid tumours (breast, colon, kidney, gastric, and lung) 
when compared with non-cancer control tissue [27]. CDC25A, a G2/M checkpoint control gene is 
regulated by miR-21, a miRNA which has been shown to be under-expressed in subset of CDC25A  
over-expressing colon cancer samples [28]. As well as representing transcriptional targets of p53, 
miRNAs miR-34a, miR-34b and miR-34c target several key mRNAs in DNA damage response itself, 
including transcripts involved in cell cycle arrest in the G1-phase or cellular apoptosis such as CDK4 
and CCNE2. Finally, transcripts coding for proteins involved in repair of damaged DNA have also 
been demonstrated to be under the control of miRNAs in HeLa and MCF-7 breast cancer cells under 
hypoxic stress; miR-210 and mi-373 have been demonstrated to target the RAD52 and RAD23B genes, 
which are involved in homologous recombination and nucleotide excision repair [29]. New evidence 
also suggests that miRNAs have a direct role in transcriptional regulation and chromatin histone 
modification, by miRNA-dependent recruitment of Argonaute to transcriptional start sites [30]. 
2.2. miRNAs and Telomere Attrition 
Ageing in man and other species is accompanied by progressive shortening of the telomere repeats 
at the end of eukaryotic chromosomes [31]. Telomeres are maintained by the binding of a complex of 
proteins which includes the TRF1 and TRF2 proteins, the telomerase protein TERT itself and 
accessory factors EST1 and dysterin [32]. Several miRNAs have been linked with telomere maintenance; 
The TRF1 gene is known to be a target of miR-155 [32] and TERT transcripts themselves are targeted 
by miR-138 in human anaplastic thyroid carcinoma cell lines [33]. In addition to its role in regulation 
of DNA damage response, the miR-34 family may also regulate telomere length; miR-34 levels were 
associated with telomere length in a series of gall bladder adenocarcinomas [34]. Telomere length must 
be carefully controlled by the cell; too few repeats and the cell will undergo premature senescence, and 
too many and the cell may not be able to adequately control cellular “lifespan” leading to diseases such 
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as cancer. Telomerase expression is only reported at high levels in the embryonic state, thereafter it is 
suppressed [35]. It is therefore easy to see how altered expression of miRNAs during ageing could 
influence the expression of telomeric components and influence cellular lifespan. 
2.3. miRNAs, Splicing and the Epigenetic Machinery 
2.3.1. miRNAs and DNA Methylation 
There is a complex interplay between miRNA regulation and epigenetics. Epigenetic changes during 
human ageing are now relatively well understood [36]. Firstly, genes encoding miRNAs, like mRNAs, 
are regulated by epigenetic changes such as altered DNA methylation. In 2006, Saito et al. demonstrated 
that levels of miR-127 were elevated in bladder carcinoma cells cultured in the presence of the DNA 
methyl-transferase inhibitor 5-aza-dC [37]. Similarly, silencing of the miR-124a, miR-34, miR-9 and 
miR-200 gene families by DNA methylation or histone modifications have been noted in several 
studies [38–41]. Secondly, miRNAs are also capable of causing aberrant DNA methylation, as well as 
being a consequence of it. The miR-29 gene family directly targets the global DNA methyltransferases 
DNMT3A and DNMT3B in lung cancer cells [42], as do miR-143, miR-148a and miR-152 in in 
colorectal cancer, malignant cholangiocytes or hepititis B induced hepatocellular carcinoma cells [43–45]. 
Changes in DNMT3 gene expression brought about by altered expression of any of these miRNAs could 
be an explanation for the changes in DNA methylation that is observed during human ageing [46]. 
2.3.2. miRNAs and Histone Modifications 
In a similar fashion to that described above, like genes encoding messenger RNAs, miRNA genes 
are also subject to regulation by histone modifications. Treatment of cell lines with compounds that 
inhibit histone deacetylases have been shown to result in altered miRNA profiles in SKBr3 breast 
cancer cells [47]. MicroRNAs miR-15a, miR-16 and miR-29 have been shown to demonstrate lower 
expression upon increased expression of HDAC1, HDAC2 and HDAC3 transcripts, which are responsible 
for histone modifications in chronic lymphocytic leukaemia samples [48]. It has also been demonstrated 
that altered miRNA expression can cause aberrant histone modifications. The EZH2 gene is a component 
of the polycomb repressive complex (PRC) which acts to trimethylate H3K27 leading to silence  
genes [49]. Several miRNAs including miR-101, miR-26a, miR-98, miR-miR-124 and miR-144 are 
thought to regulate EZH2 in various cell types including bladder transitional carcinoma, recurrent 
nasopharyngeal cancer samples and C2C12 mouse myoblasts [50–54]. Other PRC family members 
such as the BMI1 and RING2 transcripts are also subject to miRNA regulation in cancer cells in vitro 
and prostate cancer tissues [55]. Age-related alterations to the levels of miRNAs that regulate the 
global epigenetic machinery again, are likely to have profound effects on gene expression during 
ageing in man and other species. 
2.3.3. miRNAs and Regulation of Splicing 
Alternative splicing is another mechanism that allows fine tuning of gene expression and precise 
control over responses to intra- and extracellular challenges. Over 95% of human genes are alternatively 
spliced, and a proportion of these alternative isoforms will have divergent 3' UTR sequences to their 
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parent isoform. Alternative splicing paired with differential miRNA targeting of expressed isoforms 
with divergent 3' UTRs represents a potent mechanism for regulation of gene output [56]. MicroRNAs 
may also play a more direct role in the control of mRNA splicing. In a recent study, we identified that 
genes that control the splicing process were the major class of transcripts that show robust and 
reproducible expression changes with age in the human population [9,57]. Modification of levels of 
splicing regulators by the action of miRNAs is one potential explanation for this. Small RNA 
regulation of some of the splicing control proteins has previously been reported; for example, the 
ELAV transcript, which encodes the HuR protein, a major modulator of mRNA stability and translation 
in addition to mRNA splicing [58], is subject to regulation by miRNAs miR-519, miR-16 and miR-125a 
in a variety of cell types including cervical, ovarian and colon cancer cell lines [59–61]. Control of 
splice site usage is also regulated by two classes of regulator, the SR and HNRNP groups of proteins [62]. 
Several classes of mRNAs encoding SR proteins are known to be targeted by miRNAs; miR7,  
miR-10a, miR10b are known to target SRSF1, miR-193a-3p regulates SRSF2 and miR-1 targets SRSF9 
in several cell types [63] and the genes encoding hnRNPA1 and hnRNPA0 are known to be targets of 
miR-124, miR-137 and miR-340 in colon cancer cells [64]. 
2.4. miRNA Control of Proteostatic Genes 
Proteostasis is the biology of protein homeostasis. The proteostatic network consists of over  
2000 genes involved in protein modification, folding, trafficking and degradation [65]. Deregulation of 
proteostasis can lead to aberrant protein folding and aggregation, typified by the beta amyloid deposition 
and neurofibrillary tangles that characterize Alzheimer’s Disease. Chaperone systems known to be 
important in ageing include HSP40, HSP70, HSP72 and HSP90. MicroRNAs are known to regulate 
the chaperone network in several conditions including cerebral ischemia; miR-320 has been demonstrated 
to regulate HSP20 transcripts during cardiac injury [66] and miR-1 is known to target HSP72 mRNAs 
in cardiac ischemia [67]. Three miRNAs, miR-26b, miR-106a and miR301b, have been demonstrated 
to regulate HSP70 expression, and were also shown to be significantly increased in Parkinson’s disease 
patients resulting in aberrant -synuclein aggregation in Lewy bodies [68]. 
2.5. miRNAs and Nutrient Sensing Pathways 
The interplay between nutrient sensing and ageing is well described in several model organisms 
such as rodents and C.elegans [12] and has also been described in humans [13]. In particular, the only 
pharmacological intervention known to improve lifespan, rapamycin, targets the IGF-1 and mTOR 
pathways [69]. Global miRNA analysis in the skeletal muscle of young and ageing humans has 
revealed blunted miRNA responses to resistance exercise in young, but not old skeletal muscle in vivo, 
and that in particular, miR-126 emerges as an important regulator of IGF1 transcripts in muscle from 
older subjects [70]. Similar global profiling approaches have revealed other miRNAs may target the 
nutrient sensing pathways; levels of miR-190b were found to be elevated in samples from patients with 
hepatocellular carcinoma, and were demonstrated to be associated with low serum IGF1 expression 
and insulin resistance in these patients [71]. MicroRNA miR-1 has also been documented to directly 
target IGF1 transcripts in cardiac and skeletal muscle [72], as have miR-320 and miR-206 in a rat 
model of myocardial infarction [73]. MicroRNAs miR-17, miR-19b, miR-20a and miR-106a have 
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been shown to target PTEN, which encodes a major silencer of the AKT-mTOR pathway [74]. 
Alterations in the levels of these miRNA species therefore are predicted to modify the PTEN-related 
silencing of mTOR, with the effect of moderation of lifespan. These miRNAs also form a potential 
link between the DNA damage response and age-related deregulation of nutrient sensing, since p53, an 
important component of damage response is known to transcriptionally activate the miR17-92 cluster 
which encodes these miRNAs [75]. 
2.6. miRNAs Involved in Mitochondrial Dysfunction 
Mitochondrial dysfunction is a feature of ageing. During cellular metabolism, the mitochondrial 
genome is at particular risk from the reactive products of respiration, by virtue of its proximity to their 
site of production. The mitochondrion is protected from the adverse effects of free radicals and other 
reactive species by a portfolio of genes including superoxide dismutase 2 (SOD2) and thioredoxin 
reductase 2 (TRDX2) genes which encode antioxidant enzymes. Two miRNAs have been reported 
which regulate these enzymes; miR-335 and miR-34a. Ageing renal mesangial cells demonstrate 
elevated levels of both miRNAs. Overexpression of both forms in vitro led to premature cellular 
senescence, whereas antisense-mediated knockdown of miR-335 and miR-34a in old cells delayed 
cellular senescence [76]. SOD2 mRNAs are also targeted by miR-146a and altered expression of  
SOD2 mRNAs was noted upon overexpression or inhibition of this miRNA in prostate cancer PC12 
cells [77]. MicroRNA miR-145 has also been implicated in protection of cardiomyocytes against 
peroxide-induced apoptotic injury, by virtue of its repressive role in the regulation of BNIP3 
transcripts, which encode a component of the mitochrondrial apoptosis machinery [78]. 
2.7. miRNAs Involved in Cellular Senescence 
Cellular senescence is the consequence of telomere attrition, DNA damage signaling, oxidative 
stress and oncogene expression. Proteins such as p16 (encoded by CDKN2A), p53 (encoded by TP53) 
and p21 (encoded by CDKN1A) are key players in this process [79]. Components of the miRNA 
biogenesis machinery itself have been associated with cellular senescence [80]. The processes by 
which miRNAs undergo global processing and maturation of miRNAs includes the DROSHA gene 
product which cleaves the pri-miRNA to yield the pre-miRNA, and the DICER gene product which 
cleaves the Pre-miRNA to yield the mature miRNA species [81]. Loss of DICER, with its resulting 
effect on miRNA biogenesis, was found to trigger the senescence process in embryonic fibroblasts 
which results from the activation of the CDKN2A-ARF and p53 components of the DNA damage 
checkpoint [82]. Specific miRNAs have also been associated with cellular senescence. These closely 
overlap with those that regulate DNA damage checkpoints, including miR-34a, miR-24 and members 
of the miR-106b cluster [83]. Other DNA-damage associated miRNAs have also been associated with 
cellular senescence; the miR17-92 cluster and its paralogues the miR-106a and miR-106b clusters have 
also been implicated in cell senescence in several tissues and cell types [75,84]. Other studies have 
also implicated other miRNAs such as miR-29 in cellular senescence in HeLa cells and in ageing 
muscle by virtue of their effect on the expression of c-Myb mRNAs [85,86]. Decreased expression of 
these miRNAs has been shown to cause increased levels of some of their target mRNAs including 
CDKN1A [87]. 
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2.8. miRNAs and Stem Cell Exhaustion 
Unlike differentiated cells, stem cells retain the capacity for regeneration and growth. All organs 
contain stem cells, but their numbers and stem-like properties gradually decline as we age. Components 
of the miRNA biogenesis machinery have been associated with stem cell status. Several miRNAs have 
been shown to target DICER. Loss of stemness has been associated with differential expression of 
several miRNAs, notably miR-371, miR-369-5p, miR-29c, miR-499 and let-7 in mesenchymal stem 
cells [88]. The high mobility group A2 protein, encoded by the HMGA2 gene, is a potent modifier of 
chromatin structure and has also been associated with maintenance of the stem cell state. HMG2A 
transcripts are regulated by let-7 and modification of let-7 expression has been demonstrated to cause 
changes in stem cell capacity by regulating HMG2A and CDKN2A expression in mouse young adult 
stem cells [89]. 15 potential stem cell miRNAs have been identified in mouse embryonic stem cells. 
The miR-290, miR-291*, miR-292*, miR-293, miR-294, and miR-295 cluster, expressed in ES cells 
but not in differentiated mouse embryonic fibroblasts of NIH3T3 cells, are thought particularly 
important in maintenance of stem cell capacity [90]. The 290~295 cluster along with the miR-302~367 
and miR-17~92 clusters have been reported to be pivotal in maintenance of stemness in mouse 
embryonic stem cells [91]. 
2.9. miRNAs and “Inflamm-ageing” 
As we age, our general levels of inflammation increase, on a background of decreased immune 
capacity. This phenomenon is termed “inflamm-ageing”. Sensing of threat by the immune system 
results in activation of several signaling pathways, including the TOLL-like receptor (TLR) and  
the NF-b pathways [92]. There is evidence that a relatively small number of miRNAs, termed 
“inflamma-miRs” are involved in this process. The inflamma-miR group includes miR-155, miR-21 
and miR-146a [93]. MicroRNA miR-146 has been shown to regulate transcripts involved in both TLR 
and NF-b pathways in cells involved in vascular remodeling [94]. This trio of miRNAs have been 
associated with several chronic, age-related diseases in man; both miR-21 and miR-146a have been 
shown to modulate levels of pro-inflammatory cytokines in pancreatic beta cells [95], and also to show 
altered expression in plasma from patients with cardiovascular disease [96] and in cerebrospinal fluid 
and extracellular fluid from patients with Alzheimer’s disease [97]. Up-regulation of miR-155 has also 
been noted in the synovial fluid of patients with rheumatoid arthritis [98]. 
3. Conclusions 
MicroRNAs clearly have great importance in ageing, as in most other cellular processes.  
The hallmarks of ageing are known to be interconnected; for example telomere shortening is a feature 
of cellular senescence, are activation of the DNA damage response and altered cytokine profiles 
(senescent cells secrete a cocktail of cytokines termed the senescence associated secretory phenotype 
or SASP). Similarly, a number of miRNAs implicated in ageing are regulators of overlapping 
hallmarks of ageing; for example miR-34a has been implicated in mitochondrial dysfunction [76] and 
telomere attrition [34], miR-29 family members have been demonstrated to regulate DNA methylation 
genes [42] and to be linked with stem cell exhaustion [88]. MicroRNA 106 family members have been 
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shown to regulate some DNA damage response transcripts [27] as well as some mRNAs encoding 
proteostatic factors [68], whereas the miR-17, miR-19b, miR-20a and miR-106a cluster that regulate 
cellular senescence have also been shown to regulate moderators of the mTOR nutrient sensing 
pathway [75]. This suggests that the features that characterize the ageing process by miRNAs may be 
brought about by the action of an integrated and coordinated pool of miRNAs, although the precise 
make-up of that pool and the relative impact of individual miRNAs within it will probably differ from 
tissue to tissue. The presence of miRNAs associated with ageing, and the growing recognition that 
miRNAs may also circulate in the blood complexed with proteins such as Argonaute or in 
microvesicles, raises the possibility of miRNAs as possible biomarkers for healthy ageing in the future. 
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